The Taiwan Association of Diabetes Educators yesterday said it plans to work with domestic and regional partners to develop Asia’s first set of guidelines on preventing and managing side effects associated with glucagon-like peptide-1 (GLP-1) drugs.The guidelines would cover the safe use of the drug